Understanding Complex Product Characterization Analysis Session 2a
Exploring Complex Product Characterization Analysis Session 2a reveals several interesting facts. A presentation and panel discuss potential gaps in
Key Takeaways about Complex Product Characterization Analysis Session 2a
- FDA discusses topics in
- This
- Kris André, Associate Director for Regulatory Affairs in CDER OGD's Office of Research and Standards (ORS), and Katherine ...
- This
- Presentations discuss perspectives on generic industry challenges. Topics and titles as follows: Model-Integrated Evidence for ...
Detailed Analysis of Complex Product Characterization Analysis Session 2a
A presentation and panel discuss new analytical methods that are promising for generic drug development, screening, and ... A presentation and panel assess analytical methods currently considered most useful and how to better develop these ... Yiwei Li from CDER's Office of Pharmaceutical Quality shares a case study, an introduction to Iron Colloid Drug
This symposium addressed drug development of
Stay tuned for more updates related to Complex Product Characterization Analysis Session 2a.